Cargando…

Corrigendum: Inhibition of SARS-CoV-2 by Targeting Conserved Viral RNA Structures and Sequences

Detalles Bibliográficos
Autores principales:	Hegde, Shalakha, Tang, Zhichao, Zhao, Junxing, Wang, Jingxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855207/ https://www.ncbi.nlm.nih.gov/pubmed/35186888 http://dx.doi.org/10.3389/fchem.2022.842171

Ejemplares similares

Inhibition of SARS-CoV-2 by Targeting Conserved Viral RNA Structures and Sequences
por: Hegde, Shalakha, et al.
Publicado: (2021)

Chemical-guided SHAPE sequencing (cgSHAPE-seq) informs the binding site of RNA-degrading chimeras targeting SARS-CoV-2 5’ untranslated region
por: Tang, Zhichao, et al.
Publicado: (2023)

The RNA Architecture of the SARS-CoV-2 3′-Untranslated Region
por: Zhao, Junxing, et al.
Publicado: (2020)

A covalent inhibitor targeting the papain-like protease from SARS-CoV-2 inhibits viral replication
por: Han, Hesong, et al.
Publicado: (2023)

Whole genome sequencing for revealing the point mutations of SARS-CoV-2 genome in Bangladeshi isolates and their structural effects on viral proteins
por: Hossain, Mohammad Uzzal, et al.
Publicado: (2021)

Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors
por: Sargsyan, Karen, et al.
Publicado: (2020)

Targeting a conserved structural element from the SARS-CoV-2 genome using l-DNA aptamers
por: Li, Jing, et al.
Publicado: (2021)

Structural Insight Into the SARS-CoV-2 Nucleocapsid Protein C-Terminal Domain Reveals a Novel Recognition Mechanism for Viral Transcriptional Regulatory Sequences
por: Yang, Mei, et al.
Publicado: (2021)

Inhibitors of SARS-CoV-2 PLpro
por: Calleja, Dale J., et al.
Publicado: (2022)

Correction: Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors
por: Sargsyan, Karen, et al.
Publicado: (2021)

Allosteric inhibition of SARS-CoV-2 3CL protease by colloidal bismuth subcitrate
por: Tao, Xuan, et al.
Publicado: (2021)

Ethacridine inhibits SARS-CoV-2 by inactivating viral particles
por: Li, Xiaoquan, et al.
Publicado: (2021)

Pyrazolone-type compounds: synthesis and in silico assessment of antiviral potential against key viral proteins of SARS-CoV-2
por: Branković, Jovica, et al.
Publicado: (2022)

Insights into the binding and covalent inhibition mechanism of PF-07321332 to SARS-CoV-2 M(pro)
por: Ngo, Son Tung, et al.
Publicado: (2022)

Enantioselective inhibition of the SARS-CoV-2 main protease with rhenium(i) picolinic acid complexes
por: Karges, Johannes, et al.
Publicado: (2022)

Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants
por: Ferdous, Nadim, et al.
Publicado: (2021)

In silico study of the inhibition of SARS-COV-2 viral cell entry by neem tree extracts
por: Shadrack, Daniel M., et al.
Publicado: (2021)

SARS-CoV-2 genomics: An Indian perspective on sequencing viral variants
por: Srivastava, Surabhi, et al.
Publicado: (2021)

Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat
por: Hempel, Tim, et al.
Publicado: (2020)

Computational investigation on the antioxidant activities and on the M(pro) SARS-CoV-2 non-covalent inhibition of isorhamnetin
por: Spiegel, Maciej, et al.
Publicado: (2023)

Unveiling the “Template-Dependent” Inhibition on the Viral Transcription of SARS-CoV-2
por: Luo, Xueying, et al.
Publicado: (2022)

Targeting Spike Glycans to Inhibit SARS-CoV2 Viral Entry
por: Guseman, Alex J., et al.
Publicado: (2022)

XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection
por: Gerber, Pehuén Pereyra, et al.
Publicado: (2022)

Targeting spike glycans to inhibit SARS-CoV2 viral entry
por: Guseman, Alex J., et al.
Publicado: (2023)

Coding potential and sequence conservation of SARS-CoV-2 and related animal viruses
por: Cagliani, Rachele, et al.
Publicado: (2020)

Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins
por: Srinivasan, Suhas, et al.
Publicado: (2020)

Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

In silico design of peptides with binding to the receptor binding domain (RBD) of the SARS-CoV-2 and their utility in bio-sensor development for SARS-CoV-2 detection
por: Badhe, Yogesh, et al.
Publicado: (2021)

Host DDX Helicases as Possible SARS-CoV-2 Proviral Factors: A Structural Overview of Their Hijacking Through Multiple Viral Proteins
por: Squeglia, Flavia, et al.
Publicado: (2020)

Antiviral activities of natural compounds and ionic liquids to inhibit the Mpro of SARS-CoV-2: a computational approach
por: Palanisamy, Kandhan, et al.
Publicado: (2022)

Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells
por: Vanhoutte, Roeland, et al.
Publicado: (2023)

SARS-CoV-2 and viral sepsis: observations and hypotheses
por: Li, Hui, et al.
Publicado: (2020)

O-Glycosylation Landscapes of SARS-CoV-2 Spike Proteins
por: Zhang, Yong, et al.
Publicado: (2021)

Binding of inhibitors to the monomeric and dimeric SARS-CoV-2 Mpro
por: Tam, Nguyen Minh, et al.
Publicado: (2021)

Anti-HIV drug repurposing against SARS-CoV-2
por: Sang, Peng, et al.
Publicado: (2020)

Insight into prognostics, diagnostics, and management strategies for SARS CoV-2
por: Amara, Umay, et al.
Publicado: (2022)

Therapeutic potential of compounds targeting SARS-CoV-2 helicase
por: Halma, Matthew T. J., et al.
Publicado: (2022)

Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease
por: van de Sand, Lukas, et al.
Publicado: (2021)

Exploration of phenolic acid derivatives as inhibitors of SARS-CoV-2 main protease and receptor binding domain: potential candidates for anti-SARS-CoV-2 therapy
por: Shafiq, Nusrat, et al.
Publicado: (2023)

Mercapto-pyrimidines are reversible covalent inhibitors of the papain-like protease (PLpro) and inhibit SARS-CoV-2 (SCoV-2) replication
por: Bajaj, Teena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1evttrcvm18ue5nudr85q98mm1